[go: up one dir, main page]

WO2010026602A3 - Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis - Google Patents

Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis Download PDF

Info

Publication number
WO2010026602A3
WO2010026602A3 PCT/IN2009/000487 IN2009000487W WO2010026602A3 WO 2010026602 A3 WO2010026602 A3 WO 2010026602A3 IN 2009000487 W IN2009000487 W IN 2009000487W WO 2010026602 A3 WO2010026602 A3 WO 2010026602A3
Authority
WO
WIPO (PCT)
Prior art keywords
channel blockers
vgcc
calcium channel
treatment
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000487
Other languages
French (fr)
Other versions
WO2010026602A2 (en
Inventor
Shashank Gupta
Rupak Singla
Digamber Behera
U. Khayyam Khalid
Reshma Korde
Pawan Malhotra
Krishnamurthy Natarajan
Varsha Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Centre for Genetic Engineering and Biotechnology
Original Assignee
International Centre for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre for Genetic Engineering and Biotechnology filed Critical International Centre for Genetic Engineering and Biotechnology
Publication of WO2010026602A2 publication Critical patent/WO2010026602A2/en
Publication of WO2010026602A3 publication Critical patent/WO2010026602A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides calcium channel blockers for the treatment of drug sensitive and drug resistant Mycobacterium tuberculosis infection in humans and animals. In the present invention the role of L-type and R-type VGCC in M. tb infection in vitro and in vivo is disclosed. Inhibiting VGCC in DCs increases calcium influx and activates T cells that mediate killing of M. tb inside macrophages. Likewise, blocking VGCC in infected macrophages and PBMCs induces calcium influx and killing of M. tb. Blocking VGCC in vivo in M. tb infected mice using specific antibodies significantly reduces bacterial loads. Treatment of M. tb infected mice with conventional anti-TB drugs supplemented with a conventional calcium channel blockers such as amlodipine, S-amlodipine and nifedipine mediates a reduction in bacterial loads that is significantly better than drug treatment alone. In addition, these calcium channel blockers effectively kill single, multiple and extensively drug resistant stains of M. tb. Histology of spleen of different treatments indicates a marked improvement in granuloma composition with a significant decrease in cavity formation and restoration of protective granuloma architecture.
PCT/IN2009/000487 2008-09-05 2009-09-04 Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis Ceased WO2010026602A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2101DE2008 2008-09-05
IN2101/DEL/2008 2008-09-05

Publications (2)

Publication Number Publication Date
WO2010026602A2 WO2010026602A2 (en) 2010-03-11
WO2010026602A3 true WO2010026602A3 (en) 2010-10-21

Family

ID=41460540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000487 Ceased WO2010026602A2 (en) 2008-09-05 2009-09-04 Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis

Country Status (1)

Country Link
WO (1) WO2010026602A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3013734C (en) * 2009-12-03 2020-01-14 Dr. Kenneth Adams Medicine Professional Corporation Method and composition for treatment and prevention of broad spectrum virus ailments
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
EP3524237A1 (en) * 2018-02-13 2019-08-14 European Molecular Biology Laboratory Repurposing compounds for the treatment of infections and for modulating the composition of the gut microbiome
TW202227064A (en) * 2020-09-24 2022-07-16 李建璋 Prophylatic use of calcium channel blockers in tuberculosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008635A2 (en) * 1999-07-28 2001-02-08 Human Genome Sciences, Inc. Calcium channel transport polynucleotides, polypeptides, and antibodies
JP2008050270A (en) * 2006-08-22 2008-03-06 Akira Matsumori Cytokine production inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001008635A2 (en) * 1999-07-28 2001-02-08 Human Genome Sciences, Inc. Calcium channel transport polynucleotides, polypeptides, and antibodies
JP2008050270A (en) * 2006-08-22 2008-03-06 Akira Matsumori Cytokine production inhibitor

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AMINI M ET AL: "Synthesis and antitubercular activity of new N,N-diaryl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3, 5-pyridinedicarboxamides", DARU, vol. 16, no. 1, April 2008 (2008-04-01), pages 9 - 12, XP002568821, ISSN: 1560-8115 *
ANONYMOUS: "R-type Ca ++ CP alpha 1 E (C-20): sc-16225", April 2001 (2001-04-01), XP002591490, Retrieved from the Internet <URL:http://124.172.245.86/buyf/productsf/santa%20cruz/sc-16225.pdf> [retrieved on 20100712] *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, YOSHIMOTO HIROSHI ET AL: "Influence of rifampicin on antihypertensive effects of dihydropyridine calcium-channel blockers in four elderly patients", XP002568823, Database accession no. PREV199799554225 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 March 2008 (2008-03-06), MATSUMORI, AKIRA: "Cytokine production inhibitors containing nifedipine", XP002568822, retrieved from STN Database accession no. 2008:278337 *
DATABASE WPI Week 200825, Derwent World Patents Index; AN 2008-D42040 *
GOLLAPUDI S ET AL: "Mycobacterium tuberculosis Induces Expression of P-Glycoprotein in Promonocytic U1 Cells Chronically Infected with HIV Type 1", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 199, no. 3, 31 March 1994 (1994-03-31), pages 1181 - 1187, XP024764873, ISSN: 0006-291X, [retrieved on 19940331] *
MARTINS MARTA ET AL: "Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M-tuberculosis by non-killing macrophages", IN VIVO: INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL PATHOPHYSIOLOGY AND DRUG RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 22, no. 1, 1 January 2008 (2008-01-01), pages 69 - 75, XP009127687, ISSN: 0258-851X *
PORTERO J -L ET AL: "New anti-tuberculosis therapies", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 17, no. 6, June 2007 (2007-06-01), pages 617 - 637, XP002591489, ISSN: 1354-3776, DOI: 10.1517/13543776.17.6.617 *
PRAKASH JAI ET AL: "Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption", CLINICAL DRUG INVESTIGATION, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 23, no. 7, 1 January 2003 (2003-01-01), pages 463 - 472, XP009127686, ISSN: 1173-2563 *
SADIGHI AKHA AMIR A ET AL: "Anti-Ig-induced calcium influx in rat B lymphocytes mediated by cGMP through a dihydropyridine-sensitive channel", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.271.13.7297, vol. 271, no. 13, 1 January 1996 (1996-01-01), pages 7297 - 7300, XP002346482, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2010026602A2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
UA103347C2 (en) Pharmaceutical dosage form comprising nifedipine or nisoldipine and angiotensin-ii antagonist and/or diuretic
CO6311067A2 (en) PREPARATION OF TABLETS WITH DELAYED RELEASE CONTAINING POLYVINROL PIRROLIDONAS AND ACTIVE PRINCIPLE
PH12012500739A1 (en) Use of bfidobacterium longum for the prevention and treatment of inflammation
EA033370B1 (en) Formulations of rifaximin and uses thereof
WO2008142627A3 (en) Multilayered modified release formulation comprising amoxicillin and clavulanate
ZA200800176B (en) Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin II antogonist
BRPI0809656A2 (en) ATROPISOMER, COMPOUND, PROPHYLATIC OR THERAPEUTIC AGENT, AND PHARMACEUTICAL COMPOSITION
CL2012001080A1 (en) Rifaximin solid dispersion and a pharmaceutically acceptable carrier; pharmaceutical composition; use in the treatment and / or prevention of a microbial infection comprising the administration of the solid dispersion.
BR112012001987A2 (en) A compound, combination, pharmaceutical formulation, use of a compound, a combination or a pharmaceutically acceptable salt thereof, and methods for treating a bacterial infection, for killing or inhibiting the growth of a bacterium, and for inhibiting a beta-lactamase.
WO2010068810A3 (en) Certain substituted amides, method of making, and method of use thereof
HK1198869A1 (en) Combination treatments for hepatitis c
MX2010008921A (en) Oxazolidinone derivatives.
IL190478A0 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
GB2548034B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
WO2010003992A8 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
WO2011140446A3 (en) Pharmaceutical formulations
BRPI0921097A2 (en) pyrazol-3 carboxamide derivative compound with 5-ht2b receptor antagonist activity, preventive or therapeutic agent, pharmaceutical composition and use of the compound or pharmaceutically acceptable salt thereof and method or prevention or treatment.
DK2448561T3 (en) Solid pharmaceutical solid dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic use
WO2008137780A3 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
WO2010026602A3 (en) Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis
WO2009095423A3 (en) Oral care composition for combating dentine hypersensitivity
IL215840A (en) 2,5-disubstituted arylsulfonamide compounds, pharmaceutical compositions comprising same and use thereof in treating ccr3-related diseases
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
BRPI1008103A2 (en) &#34;isolated short chain peptide, pharmaceutical composition, compounds, method of preventing or treating diseases, medicament for treating / reducing medical conditions and use of the compounds&#34;

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09741002

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09741002

Country of ref document: EP

Kind code of ref document: A2